Back

Novel potassium binders help optimize RAASi therapy in heart failure patients: a systematic review and meta-analysis of RCT

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy Cardiovascular Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Christian Basile

Karolinska Institute, Stockholm (Sweden)

6 More presentations in this session

Presentation thumbnail
Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
Doctor D. Stolfo (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial
Doctor S. Chatur (Boston, US)
Abstract Slides Video
Presentation thumbnail
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
Doctor J. Tromp (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
Ms I. Beldhuis (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy
Video

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources